SARNS ARTERIAL CANNULAE WITH DURAFLO TREATMENT

K964373 · 3M Healthcare · DWF · Jun 18, 1997 · Cardiovascular

Device Facts

Record IDK964373
Device NameSARNS ARTERIAL CANNULAE WITH DURAFLO TREATMENT
Applicant3M Healthcare
Product CodeDWF · Cardiovascular
Decision DateJun 18, 1997
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.4210
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Sarns Aortic Arch Cannulae with Duraflo Treatment, Flexible Arterial Cannulae with Duraflo Treatment, High Flow Aortic Arch Cannulae with Duraflo Treatment, Soft Arc Cannula with Duraflo Treatment, D4 Cannulae with Duraflo Treatment, and the Soft Flow Cannulae with Duraflo Treatment are indicated for use in perfusion of the ascending aorta during cardiopulmonary bypass surgery. The Sarns Flexible Aortic Arch Cannula with Duraflo Treatment is indicated for use in perfusion of the descending thoracic aorta during cardiopulmonary bypass surgery.

Device Story

Sarns Arterial Cannulae are sterile, single-use devices used during cardiopulmonary bypass surgery to perfuse the ascending or descending thoracic aorta. The device consists of a cannula tip, tube, and connector, available in various sizes (3.8 mm to 8.0 mm OD), styles (straight/angled, soft/rigid, metal/plastic), and construction (wire-reinforced or non-wire-reinforced). Some models include an optional suture flange or Luer port for air venting. The subject devices incorporate Duraflo Treatment, which deposits a heparin layer on internal and external surfaces to improve hemocompatibility. The device is operated by clinical staff in a surgical setting. It functions as a conduit for blood flow during bypass, with the heparin coating intended to reduce thrombogenicity.

Clinical Evidence

No clinical data. Bench testing only.

Technological Characteristics

Sterile, single-use arterial cannulae. Materials include metal or plastic tips, wire-reinforced or non-wire-reinforced tubing. Features heparin-based Duraflo treatment applied to internal and external surfaces. Dimensions range from 3.8 mm to 8.0 mm outer diameter. No dimensional changes compared to predicate devices.

Indications for Use

Indicated for perfusion of the ascending aorta during cardiopulmonary bypass surgery; Sarns Flexible Aortic Arch Cannula also indicated for perfusion of the descending thoracic aorta during cardiopulmonary bypass surgery.

Regulatory Classification

Identification

A cardiopulmonary bypass vascular catheter, cannula, or tubing is a device used in cardiopulmonary surgery to cannulate the vessels, perfuse the coronary arteries, and to interconnect the catheters and cannulas with an oxygenator. The device includes accessory bypass equipment.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JUN 18 1997 Mr. Jason Smith Regulatory Affairs Coordinator 3M Health Care Cardiovascular Systems Sarns and CDI Products 6200 Jackson Road Ann Arbor, Michigan 48103-9300 Re: K964373 Sarns Arterial Cannulae with Duraflo® Treatment Regulatory Class: II (Two) Product Code: 74 DWF Dated: April 9, 1997 Received: April 10, 1997 Dear Mr. Smith: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {1} Page 2 - Mr. Jason Smith This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for *in vitro* diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "dsmo@fdadr.cdrh.fda.gov." Sincerely yours, ![img-0.jpeg](img-0.jpeg) Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2} 510(k) Number (if known): K 964373/5001 Device Name: Sarns Arterial Cannulae with Duraflo Treatment ## Indications For Use: The Sarns Aortic Arch Cannulae with Duraflo Treatment, Flexible Arterial Cannulae with Duraflo Treatment, High Flow Aortic Arch Cannulae with Duraflo Treatment, Soft Arc Cannula with Duraflo Treatment, D4 Cannulae with Duraflo Treatment, and the Soft Flow Cannulae with Duraflo Treatment are indicated for use in perfusion of the ascending aorta during cardiopulmonary bypass surgery. The Sarns Flexible Aortic Arch Cannula with Duraflo Treatment is indicated for use in perfusion of the descending thoracic aorta during cardiopulmonary bypass surgery. ( PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED ) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number K 964373 Description Use ☑ Order 21 CFR 801.109) OR Over-The-Counter Use (Optional Format 1-2-96) {3} JUN 18 1997 510(k) SUMMARY k964373 This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is _______________. Submitter's Name: 3M Health Care Submitter's Address: 6200 Jackson Road, Ann Arbor, Michigan 48103 Contact Person: Jason Smith Phone Number: (313) 663-4145 FAX Number: (313) 663-5062 Summary Date: ## Device Trade Names: Sarns Aortic Arch Cannulae with Duraflo® Treatment, Sarns Flexible Aortic Arch Cannula with Duraflo® Treatment, Sarns Flexible Arterial Cannulae with Duraflo® Treatment, Sarns High Flow Aortic Arch Cannulae with Duraflo® Treatment, Sarns Soft-Arc Cannula with Duraflo® Treatment, Sarns D4 Cannulae with Duraflo® Treatment, Sarns Soft Flow Cannulae with Duraflo® Treatment ## Device Classification Name: "Cardiopulmonary Bypass Vascular Catheter, Cannula, or Tubing" (21 CFR 870.4210) ## Predicate Devices: The Sarns Arterial Cannulae with Duraflo® Treatment are substantially equivalent to the existing Sarns Arterial Cannulae [510(k) clearance numbers listed in the table below]. | Cannula Type | 510(k) Number | Clearance Date | | --- | --- | --- | | Soft Flow | K934127 | 2/22/94 | | D4 | K874896 | 2/2/88 | | Soft-Arc | K834134 | 4/17/84 | | Flexible Arterial | K771499 | 8/16/77 | | High Flow Aortic Arch | K770429 | 3/16/77 | | Aortic Arch, Flexible Aortic Arch | Preamendment | | ## Device Description: The only difference between the Sarns Arterial Cannulae and the Sarns Arterial Cannulae with Duraflo® Treatment is the addition of the Duraflo® Treatment. As a result of this process, a layer of heparin is deposited on the inside and outside of the cannula tip, tube, and connector. Like their predicate devices, the Sarns Arterial Cannulae with Duraflo® Treatment are sterile, single-use medical devices. They are available in sizes ranging from 3.8 mm to 8.0 mm outer diameter tip sizes, with tips being straight or angled, soft or rigid, metal or plastic. Several styles of the Sarns Arterial Cannulae are available in both wire-reinforced and non-wire-reinforced tube styles. Other features include an Page 14 of 210 {4} optional suture flange on some models as well as an optional Luer port for the venting of air. ## Indications for Use: The Sarns Aortic Arch, Flexible Aortic Arch, High Flow Aortic Arch, Flexible Arterial, D4, and Soft Flow Cannulae with Duraflo® Treatment are indicated for use in perfusion of the ascending aorta during cardiopulmonary bypass surgery. The Sarns Flexible Aortic Arch Cannula with Duraflo® Treatment is indicated for use in perfusion of the descending thoracic aorta during cardiopulmonary bypass surgery. ## Technological Characteristics: The only difference between the Sarns Arterial Cannulae and the Sarns Arterial Cannulae with Duraflo® Treatment is the addition of the Duraflo® Treatment. As a result of this process, a layer of heparin is deposited on the inside and outside of the cannula tip, tube, and connector. There will be no dimensional changes to the cannulae due to the addition of the Duraflo® Treatment ## Nonclinical Performance: The performance characteristics of selected models (these models were chosen as being representative of the technological attributes of all models of Sarns Arterial Cannulae) of the Sarns Arterial Cannulae with Duraflo® Treatment were exhaustively tested and compared with the performance characteristics of the currently marketed Sarns Arterial Cannulae. All new and existing performance characteristics of the Sarns Arterial Cannulae with Duraflo® Treatment have been validated. ## Clinical Performance: Clinical testing was not performed on these devices. ## Conclusions from Nonclinical Tests: The Sarns Arterial Cannulae with Duraflo® Treatment perform as intended according to their performance specifications. The Sarns Arterial Cannulae with Duraflo® Treatment are substantially equivalent to their predicate devices. Page 15 of 210
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%